BR0317280A - Prevention and treatment of alzheimer's disease - Google Patents
Prevention and treatment of alzheimer's diseaseInfo
- Publication number
- BR0317280A BR0317280A BR0317280-5A BR0317280A BR0317280A BR 0317280 A BR0317280 A BR 0317280A BR 0317280 A BR0317280 A BR 0317280A BR 0317280 A BR0317280 A BR 0317280A
- Authority
- BR
- Brazil
- Prior art keywords
- alzheimer
- treatment
- prevention
- inhibitor
- disease
- Prior art date
Links
- 230000002265 prevention Effects 0.000 title abstract 3
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 abstract 1
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 abstract 1
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 abstract 1
- 229940123239 Cholesterol synthesis inhibitor Drugs 0.000 abstract 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 abstract 1
- 229940121773 Secretase inhibitor Drugs 0.000 abstract 1
- 239000003613 bile acid Substances 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 abstract 1
- 230000000968 intestinal effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Abstract
"PREVENçãO E TRATAMENTO DO MAL DE ALZHEIMER". A presente invenção refere-se à aplicação dos inibidores de recaptura intestinal do ácido biliar para a prevenção e o tratamento do Mal de Alzheimer, se for o caso em associação com um inibidor de HMG-CoA reductase, um inibidor da captura de colesterol, um inibidor da síntese de colesterol ou um inibidor dos APP secretases."ALZHEIMER EVIL PREVENTION AND TREATMENT". The present invention relates to the application of bile acid intestinal reuptake inhibitors for the prevention and treatment of Alzheimer's Disease, if appropriate in combination with a HMG-CoA reductase inhibitor, a cholesterol capture inhibitor, a cholesterol synthesis inhibitor or an APP secretase inhibitor.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0215722A FR2848452B1 (en) | 2002-12-12 | 2002-12-12 | APPLICATION OF INTESTINAL BILIARY ACID RECAPTURE INHIBITORS FOR THE PREVENTION AND TREATMENT OF ALZHEIMER'S DISEASE |
| PCT/FR2003/003654 WO2004062652A1 (en) | 2002-12-12 | 2003-12-10 | Prevention and treatment of alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0317280A true BR0317280A (en) | 2005-11-08 |
Family
ID=32338722
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0317280-5A BR0317280A (en) | 2002-12-12 | 2003-12-10 | Prevention and treatment of alzheimer's disease |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP1572174A1 (en) |
| JP (1) | JP2006514063A (en) |
| KR (1) | KR20050084250A (en) |
| CN (1) | CN1726016A (en) |
| AR (1) | AR042354A1 (en) |
| AU (1) | AU2003296802A1 (en) |
| BR (1) | BR0317280A (en) |
| CA (1) | CA2507945A1 (en) |
| CO (1) | CO5700712A2 (en) |
| FR (1) | FR2848452B1 (en) |
| HR (1) | HRP20050534A2 (en) |
| MA (1) | MA27500A1 (en) |
| MX (1) | MXPA05005556A (en) |
| NO (1) | NO20053341L (en) |
| NZ (1) | NZ540496A (en) |
| PE (1) | PE20040770A1 (en) |
| PL (1) | PL377110A1 (en) |
| RS (1) | RS20050420A (en) |
| RU (1) | RU2005121909A (en) |
| TW (1) | TW200503707A (en) |
| WO (1) | WO2004062652A1 (en) |
| ZA (1) | ZA200504656B (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7521481B2 (en) | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
| WO2005049027A2 (en) | 2003-11-03 | 2005-06-02 | Probiodrug Ag | Combinations useful for the treatment of neuronal disorders |
| BRPI0507485A (en) | 2004-02-05 | 2007-07-10 | Probiodrug Ag | new glutaminyl cyclase inhibitors |
| ATE523199T1 (en) | 2004-11-02 | 2011-09-15 | Univ Northwestern | PYRIDAZINE COMPOUNDS AND METHODS |
| US8158627B2 (en) | 2006-04-28 | 2012-04-17 | Northwestern University | Compositions and treatments using pyridazine compounds and cholinesterase inhibitors |
| RU2469723C2 (en) * | 2007-05-22 | 2012-12-20 | Оцука Фармасьютикал Ко., Лтд. | Therapeutic agent containing carbostiryl derivative and donepezil for treating alzheimer's disease |
| EP2770990A4 (en) | 2011-10-28 | 2015-03-11 | Lumena Pharmaceuticals Inc | BILY ACID RECYCLING INHIBITORS FOR THE TREATMENT OF HYPERCHOLEMIA AND HEPATIC CHOLESTATIC DISEASE |
| PT2771003T (en) * | 2011-10-28 | 2017-07-26 | Lumena Pharmaceuticals Llc | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2040996A1 (en) * | 1990-05-02 | 1991-11-03 | Robert L. Albright | Composition and method for controlling cholesterol |
| CA2104594C (en) * | 1991-02-22 | 2004-05-11 | Howard K. Shapiro | Use of pharmaceutical compounds in the treatment of symptoms of disorders related to neurological diseases and etiologically related symptomology |
| AU3649697A (en) * | 1996-06-27 | 1998-01-14 | G.D. Searle & Co. | Particles comprising amphiphilic copolymers, having a cross-linked shell domain and an interior core domain, useful for pharmaceutical and other applications |
| US5985936A (en) * | 1997-12-18 | 1999-11-16 | Forbes Medi-Tech, Inc. | Method of preventing and delaying onset of Alzheimer's disease and composition therefor |
| EP1051161B1 (en) * | 1998-01-28 | 2006-03-22 | Warner-Lambert Company Llc | Method for treating alzheimer's disease |
| US6080778A (en) * | 1998-03-23 | 2000-06-27 | Children's Medical Center Corporation | Methods for decreasing beta amyloid protein |
| US6221897B1 (en) * | 1998-06-10 | 2001-04-24 | Aventis Pharma Deutschland Gmbh | Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use |
| DE19825804C2 (en) * | 1998-06-10 | 2000-08-24 | Aventis Pharma Gmbh | 1,4-Benzothiepin-1,1-dioxide derivatives, processes for their preparation and medicaments containing these compounds |
| DE19845405C2 (en) * | 1998-10-02 | 2000-07-13 | Aventis Pharma Gmbh | Aryl-substituted propanolamine derivatives and their use |
| US20010028895A1 (en) * | 2000-02-04 | 2001-10-11 | Bisgaier Charles L. | Methods of treating alzheimer's disease |
| US20020028826A1 (en) * | 2000-06-15 | 2002-03-07 | Robl Jeffrey A. | HMG-CoA reductase inhibitors and method |
| SE0104334D0 (en) * | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
| TWI329111B (en) * | 2002-05-24 | 2010-08-21 | X Ceptor Therapeutics Inc | Azepinoindole and pyridoindole derivatives as pharmaceutical agents |
-
2002
- 2002-12-12 FR FR0215722A patent/FR2848452B1/en not_active Expired - Fee Related
-
2003
- 2003-12-10 WO PCT/FR2003/003654 patent/WO2004062652A1/en not_active Ceased
- 2003-12-10 RU RU2005121909/15A patent/RU2005121909A/en not_active Application Discontinuation
- 2003-12-10 NZ NZ540496A patent/NZ540496A/en unknown
- 2003-12-10 CA CA002507945A patent/CA2507945A1/en not_active Abandoned
- 2003-12-10 RS YUP-2005/0420A patent/RS20050420A/en unknown
- 2003-12-10 PE PE2003001247A patent/PE20040770A1/en not_active Application Discontinuation
- 2003-12-10 AU AU2003296802A patent/AU2003296802A1/en not_active Abandoned
- 2003-12-10 AR ARP030104540A patent/AR042354A1/en not_active Application Discontinuation
- 2003-12-10 HR HR20050534A patent/HRP20050534A2/en not_active Application Discontinuation
- 2003-12-10 JP JP2004566119A patent/JP2006514063A/en not_active Abandoned
- 2003-12-10 EP EP03815109A patent/EP1572174A1/en not_active Withdrawn
- 2003-12-10 KR KR1020057010595A patent/KR20050084250A/en not_active Withdrawn
- 2003-12-10 BR BR0317280-5A patent/BR0317280A/en not_active IP Right Cessation
- 2003-12-10 PL PL377110A patent/PL377110A1/en not_active Application Discontinuation
- 2003-12-10 CN CNA2003801059727A patent/CN1726016A/en active Pending
- 2003-12-10 MX MXPA05005556A patent/MXPA05005556A/en not_active Application Discontinuation
- 2003-12-11 TW TW092134949A patent/TW200503707A/en unknown
-
2005
- 2005-06-07 ZA ZA200504656A patent/ZA200504656B/en unknown
- 2005-06-09 CO CO05056010A patent/CO5700712A2/en not_active Application Discontinuation
- 2005-06-10 MA MA28329A patent/MA27500A1/en unknown
- 2005-07-08 NO NO20053341A patent/NO20053341L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| RU2005121909A (en) | 2006-01-20 |
| NO20053341L (en) | 2005-09-07 |
| KR20050084250A (en) | 2005-08-26 |
| NZ540496A (en) | 2008-04-30 |
| FR2848452B1 (en) | 2007-04-06 |
| RS20050420A (en) | 2007-04-10 |
| FR2848452A1 (en) | 2004-06-18 |
| CO5700712A2 (en) | 2006-11-30 |
| AR042354A1 (en) | 2005-06-15 |
| AU2003296802A1 (en) | 2004-08-10 |
| JP2006514063A (en) | 2006-04-27 |
| MA27500A1 (en) | 2005-08-01 |
| CA2507945A1 (en) | 2004-07-29 |
| WO2004062652A1 (en) | 2004-07-29 |
| ZA200504656B (en) | 2006-08-30 |
| PL377110A1 (en) | 2006-01-23 |
| MXPA05005556A (en) | 2005-07-26 |
| TW200503707A (en) | 2005-02-01 |
| CN1726016A (en) | 2006-01-25 |
| HRP20050534A2 (en) | 2006-11-30 |
| NO20053341D0 (en) | 2005-07-08 |
| PE20040770A1 (en) | 2004-12-10 |
| EP1572174A1 (en) | 2005-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT1509232E (en) | A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer`s disease | |
| BR0206654A (en) | Combinations of peroxisome proliferation-activated receptor (s) activator (s) and sterol absorption inhibitor (s) and treatments for vascular indications | |
| TNSN01125A1 (en) | PHARMACEUTICAL COMPOSITIONS COMPRISING A CETP AND ATORVASTATIN INHIBITOR | |
| BR0312421A (en) | Use of cept inhibitors and optionally hmg coa reductase inhibitors and / or antihypertensive agents | |
| BRPI0412439A (en) | compounds and compositions comprising sterols and / or stanols and cholesterol biosynthesis inhibitors and their use in the treatment or prevention of a variety of diseases and conditions. | |
| BRPI0407993A (en) | p38 inhibitors and methods for using them | |
| DE60312017D1 (en) | SULPHONE DERIVATIVES FOR INHIBITING GAMMA SECRETASE | |
| BR0317280A (en) | Prevention and treatment of alzheimer's disease | |
| ATE463254T1 (en) | ANTIBODIES AGAINST PHOSPHORYLCHOLINE CONJUGATES | |
| NO20075801L (en) | Method of treating or preventing bone destruction or osteoporosis | |
| EP1708719A4 (en) | AQUEOUS PHARMACEUTICAL COMPOSITIONS OF 2,6-DIISOPROPYLPHENOL (PROPOFOL) AND USES THEREOF | |
| BR0316723A (en) | Anilinopyrazole derivatives useful for the treatment of diabetes | |
| UA101556C2 (en) | COMBINED APPLICATION OF PDE 4 INHIBITOR AND HMG-COA REDUCTASE INHIBIT FOR PREVENTION OR HEALING TREATMENT OF INFECTIOUS DISEASE | |
| EP2862867A3 (en) | Methods and compositions for the treatment of Marfan syndrome and associated disorders | |
| EP1865972A4 (en) | TREATMENT OR PREVENTION OF CANCER AND PRECANCEROUS DISORDERS | |
| BRPI0519919A2 (en) | pharmaceutical compositions comprising nep inhibitors, endogenous endothelin production system inhibitors and hmg coa reductase inhibitors | |
| MA29531B1 (en) | NEW PROCESS FOR TREATING HYPERLIPIDEMIA | |
| BR9808784A (en) | Method for the treatment of mental illness in mammals and a composition for the same | |
| TW200806293A (en) | Methods of treatment with CETP inhibitors | |
| EP1488808A4 (en) | MEANS FOR THE TREATMENT OF GLOMERULAR DISEASES | |
| BRPI0507859A (en) | use of cholinesterase inhibitors | |
| WO2008137636A3 (en) | Compositions and methods for identifying and treating subjects at risk of developing type 2 diabetes | |
| WO2004028456A3 (en) | Method and composition for treating neurodegenerative disorders | |
| BR0304144C1 (en) | compression plate for bone fixation | |
| EP1548445A3 (en) | Novel targets for obesity from fat tissue |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A E 7A ANUIDADE(S). |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2073 DE 28/09/2010. |